Results 201 to 210 of about 34,445,663 (284)

Energy-Metabolism-Enhancing Probiotics Enhance the Therapeutic Response to a Glucagon-like Peptide-1 Receptor Agonist. [PDF]

Nutrients
Kim AR, Jeon SG, Park SJ, Kim BK, Kweon MN, Jang MH, Yang BG.   +6 more
europepmc   +1 more source

It's a game changer in terms of diabetic management’: A qualitative study of adolescents' and parents' experiences of a 6‐month trial of continuous glucose monitoring in type 2 diabetes

Diabetic Medicine, EarlyView.
Abstract Aim To qualitatively explore adolescents with type 2 diabetes (T2D) using any treatment regimen and parents of such adolescents' experiences of a 6‐month trial of continuous glucose monitoring (CGM) and its perceived barriers and facilitators.
Maheesha Fernando, Alexia S. Peña, Ashlee King, Melissa Oxlad   +3 more
wiley   +1 more source

The association between glucagon-like peptide-1 receptor agonist and rheumatoid arthritis: a population-based case-control study. [PDF]

Ther Adv Musculoskelet Dis
Israel A, Hassan F, Merzon E, Kurtam J, Awad J, Assalia M, Green I, Vinker S, Naffaa ME.   +8 more
europepmc   +1 more source

Therapies for Cardiovascular‐Kidney‐Liver‐Metabolic Syndrome: Reappraisal of Fibrates

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Cardiovascular disease, chronic kidney disease (CKD), type 2 diabetes mellitus (T2DM), obesity and metabolic dysfunction‐associated steatohepatitis (MASH) frequently coexist and share overlapping pathophysiology, forming the proposed cardiovascular‐kidney‐liver‐metabolic (CKLM) syndrome.
Virginia Anagnostopoulou, Christoforos K. Travlos, Lucas Lage Marinho, Thomas A. Mavrakanas, João Pedro Ferreira, Abhinav Sharma   +5 more
wiley   +1 more source

Body Mass Index-Dependent Effect of Glucagon-Like Peptide 1 Receptor Agonist Therapy on Bowel Preparation Quality. [PDF]

Clin Transl Gastroenterol
Vikash FNU, Valencia S, Yang Q, Rubin S, Garg S.   +4 more
europepmc   +1 more source

Assessment of thyroid cancer risk associated with glucagon-like peptide 1 receptor agonist use. [PDF]

Diabetes Obes Metab
Vilsbøll T, Stellfeld M, Aroda VR, Dandanell S, David JP, Kristiansen CTP, Rasmussen S, Roberts FL, Hegedüs L.   +8 more
europepmc   +1 more source

Association of GLP-1 receptor agonist use with cardiovascular outcomes in patients with non-obstructive hypertrophic cardiomyopathy

American Journal of Preventive Cardiology
Harshvir S. Bal, Amrita Nayak, Akhil Pampana, Sindhoosha Malay, Astha Upadhyaya, Nehal Vekariya, Garima Arora, Pankaj Arora   +7 more
doaj   +1 more source

Evaluating Glucagon-Like Peptide-1 Receptor Agonist Safety Before Upper Endoscopy: A Systematic Review and Meta-Analysis. [PDF]

Gastroenterology Res
Ahmed Z, Iqbal A, Ghazaleh S, Kobeissy A, Nawras A, Alastal Y, Saad H, Mansur S, Mohiuddin I, Iqbal U, Dahiya DS, Arif SF, Campbell C, Lee-Smith W, Asif MW, Kamal F, Saeed A, Horani O.   +17 more
europepmc   +1 more source

Incretin‐Based Therapies as Cardiometabolic Interventions: Outcome Hierarchy, Receptor‐Network Pharmacology and Phenotype‐Based Clinical Positioning

Diabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims Incretin‐based pharmacotherapy was initially developed to improve glucose‐dependent insulin secretion and glycaemic control in type 2 diabetes, but its clinical interpretation has expanded substantially with cardiovascular outcome trials, kidney outcome data, obesity studies and next‐generation polyagonist development.
Ferenc Sztanek, Hajnalka Lőrincz, Mariann Harangi, Attila Csaba Nagy   +3 more
wiley   +1 more source

Acute glucagon-like peptide-1 receptor agonist, semaglutide, attenuates cue-, drug-, and stress-induced fentanyl seeking in male Sprague-Dawley rats. [PDF]

Behav Pharmacol
Evans B, Acharya N, Brandl CG, Shealy EG, Nyland JE, Freet CS, Bunce SC, Grigson PS.   +7 more
europepmc   +1 more source